MDGL Madrigal Pharmaceuticals Inc

$MDGL called Intercept Pharmaceuticals safety and efficacy problems out several years before their downfall. Now this potential fraud. Extremely astute. And people still don't listen to him You do you! Good luck! Long $GALT

$MDGL MDGL bulls, All u see is what MDGL wants u to see. The lawsuit does not come from some midlevel employee but from a highly respected KOL Hepatologist, Dr. Michael Charlton. I posted an early report published in Hepatology Communications from the State of Indiana that reported on high discontinuation rates with Rezdriffa. Would also recommend going to the FDA VAERS database and seeing how many AEs or SAEs have been reported. Note the CEO does not tell you how many pts discontinued Rez because of side effects. As an investor in biotech, common to see lawsuits being filed, and many are frivolous, but given Charlton's position in the company at the time, as well as his outstanding reputation, this should be taken seriously.

$MDGL people seem very confused about what charlton is alleging in his complaint. He is not arguing that MDGL suppressed safety data, rather that data from insurance coverage showed that 7% of patients being prescribed Rez are f4 patients and this means that their doctors are prescribing it off label to these patients. This is of no fault to MDGL. Charlton alleges that when he investigated liver imjuries in that 7% who are prescribed rez off label for f4c, DILI and decompensation rates were higher. He wanted MDGL to ”sound the alarm” about this. They told him to stop looking into this because its not their responsibility if doctors prescribe off label and because DILI already occur at higher rates in this set of patients. He alleges 3 other main things in his complaint but this is the one regarding data safety “suppression”

$MDGL If there is going to be a BO here, will not happen until the results of the Outcomes Trial is known, which is the end of 2027.

$MDGL juicy allegations in the lawsuit. Founder editing SAE case reports, tampering with safety data…Rave or whatever reporting system they use to capture data would have audit trails. Safety data likely in multiple databases accessible by many different roles. Curious what evidence/records this guy collected before he left? Site, CRO, Sponsor, 3rd party vendors (I.e stats) all play a role. And only he finds / sees the problem…Site PI would know their patients and events…seems like a high bar for this guy to make a case.

$MDGL Talked to physicians from my clinic who attended AASLD over the weekend. They said the majority of hepatologists in the circles they run in dont buy the ’news’ from last week. They did say there was a guy in a cat costume protesting. 😂😂😂 Todays price action confirms the general sentiment from the meeting.

$MDGL so this was filed in early October and only surfaces today when great er was released? Nothing suspicious about it.

$MDGL Big support right during the Liver Meeting from Baker Brothers. Interesting? Charlton alleges: * Suppression of liver injury safety information. * Problems identifying hepatic decompensation. * Potential interference with blinded clinical-trial adjudication. * Inability to reproduce certain efficacy results presented at EASL. * Management interference after he raised concerns. These are serious allegations involving the scientific integrity of the clinical data supporting Rezdiffra. Madrigal disputes the allegations. They do remain unproven.

$MDGL Let’s be clear I’m not making any allegations at all. I’m highlighting the allegations made in a lawsuit by former company employee Dr. Michael R. Charlton, MBBS, FRCP, he is a gastroenterologist, hepatologist, and liver transplantation specialist. University of Chicago Professor of Medicine, Chief of Hepatology, Director of the Center for Liver Diseases, and Medical Director of the Transplant Institute He was Senior Vice President of Clinical Development at Madrigal appointed October 2024 past Academic leadership roles at the Mayo Clinic (Director of Hepatology) and Intermountain Medical Center. The Case No. IS 1:26-cv-12410, N.D. Ill., LAWSUIT WAS filed 10/09/26

$MDGL To be clear this alleges a pattern of data manipulation in my opinion and review of the case. If true it’s not small. It would be one of the bigger scandals in the history of biotech if the allegations are true. • Safety cases across four trials. Concerns about liver-injury assessments came up in studies 11, 14, 18 and 19. Charlton raised them on four dates between October 2024 and January 2025 (¶63). According to the complaint, all potential liver-injury cases went through Dr. Taub's pre-screening and editing (¶66). • The EASL presentation. Almost no data point could be reproduced from the source data, and every discrepancy made the drug look better (¶83, 87). The same data was then reused at several later meetings and shown to investors (¶92).

$MDGL When similar happened to ICPT (allegations of covering up toxic effects), it kept its stock price initially and then collapsed.

$MDGL Well well. It appears the doom and gloom shorts have run out of fresh ammo and have slinked back to their holes (and the GALT board). 😂 The Big $ players and wallstreet firms have now done their digging and appear to be comfortable with the situation. Shorts who got in in below $370 are getting toasted

$MDGL I think I’ll take my cues on MDGL from Baker Bros not some dude with a cat fetish. Just sayin.

$MDGL is becoming an interesting growth story. Q3 revenue surged 50% YoY to $431.3M, Rezdiffra crossed $1.1B in YTD sales, and Madrigal recorded its first profitable quarter.$600 is looking increasingly achievable over the next 6–12 months. $800? An ambitious upside target. Watching closely.

$MDGL same thing happened last ER. Stock dived from 550 to 455 and then went back to 520 or so. I woukd think this is an opportunity to add

$MDGL If there had been a large number of unreported serious adverse events, why didn’t Charlton turn to the FDA? His lawsuit seeks reinstatement or damages—but why would he want to be reinstated if the drug, due to these adverse events, is a failure?

$MDGL Oct 9 2026, Frontiers in Pharmacology "Real world pharmacovigilance and cross-data base assessment of resmetirom- related adverse events using FAERS and VigiAccess"

$MDGL This is a civil case that can be settled at any time. Congratulations to the shorts for successfully stirring a storm in a tea cup for the benefit of the longs who can now take advantage of the fire sale. BUY THE DIP!

$MDGL • Charlton v. Madrigal Pharmaceuticals: More recently, in October 2026, Dr. Michael R. Charlton (former Head of Clinical Development) filed a civil rights-related lawsuit against the company in the Illinois Northern District Court. 💼 Why This Matters for Investors (and Why It Doesn't for the Drug) • Zero Operational Impact on Rezdiffra: These are standard internal civil rights and employment disputes regarding executive severance, termination fairness, and workplace conduct. They do not target the efficacy, clinical manufacturing, or safety standards of the actual medicine.

$MDGL MDGL's conference this morning ought to make any investor excited, yet the share price is heading South, why? So CEO stated, market penetration remains at 1%. There was no mention at all of EMA, implying that it will be a slog, and Medicare remibursement contracts until mid 2027. Endocronologists are not yet totall on board, but they are working on it. Most investors do not realize that this speciality might view Rez differently vs. GE/HEPs. Look at Dr. Cusi's editorial in NEJM discussing MDGL's fibrosis PBO subtracted response rate only 10-11%. Gross to net improved but still not where some analysts would like it to be. Then there is this new CSPH trial, but its built on a questionalbe foundation, an open label trial of only n=122 pts where they reported that 65% of the pts meeting BAVENO criteria for CSPH moved to lower-risk categories based on LSM & PLT count, but that is very different from proving a 65% reduction in CSPH outcomes.